Coya Therapeutics即将进行的II期临床试验旨在评估COYA 302在ALS患者中的有效性和安全性，NEALS联盟接受为NEALS附属试验

NEALS, the world's largest ALS research consortium, has selected the COYA 302 trial and it is now affiliated with NEALS as part of its mission to accelerate the development of new treatments for people living with ALS;

Following FDA's recent acceptance of the COYA 302 IND, Coya plans to initiate its Phase 2 study in people with ALS in Q4 2025;

The COYA 302 study will be presented during the NEALS Educational Webinar on September 29, 2025.

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced that its upcoming Phase 2 clinical trial to evaluate the efficacy and safety of COYA 302 in patients with ALS has been accepted as a NEALS-Affiliated Trial by the NEALS Consortium.